Succinic Acid

Succinic Acid

SCHEMBL812815

O=C(O)CC(=O)O.O=C(O)CCC(=O)O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.75
LMNA P02545 5/20 0.75
LDHA P00338 1/20 0.75
SRR Q9GZT4 1/20 0.75
ALKBH5 Q6P6C2 1/20 0.75
SUCNR1 Q9BXA5 1/20 0.75
PHF8 Q9UPP1 6/20 0.56
KDM2A Q9Y2K7 6/20 0.56
KDM4E B2RXH2 4/20 0.56
KDM5C P41229 4/20 0.56
KDM6B O15054 2/20 0.56
FOLH1 Q04609 1/20 0.56
SLC22A6 Q4U2R8 1/20 0.53
SLC15A2 Q16348 1/20 0.53
MAPK1 P28482 1/20 0.53
SLC13A3 Q8WWT9 1/20 0.53
OR51E2 Q9H255 1/20 0.53
TSHR P16473 2/20 0.50
NFKB1 P19838 1/20 0.50
PMP22 Q01453 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL1235179 1.00 EGLN1 (0.75) EGLN1LMNALDHASRRALKBH5
Malonic Acid SCHEMBL336 0.87
Succinic Acid SCHEMBL21867134 0.87 LMNA (1.00) EGLN1LMNALDHASRRALKBH5
Succinic Acid SCHEMBL3799615 0.87
Succinic Acid SCHEMBL24696 0.87 LMNA (1.00) EGLN1LMNALDHASRRALKBH5
Malonic Acid SCHEMBL1332554 0.87
Malonic Acid SCHEMBL1332587 0.87
Malonic Acid SCHEMBL1332405 0.87
Succinic Acid SCHEMBL4269135 0.87 LMNA (1.00) EGLN1LMNALDHASRRALKBH5
Malonic Acid SCHEMBL3358611 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4250922-A1 SURFACE MODIFICATION TO REGULATE PLANT GROWTH Bind-X GmbH (DE) 2023-10-04 EP claimed
WO-2022111788-A1 SURFACE MODIFICATION TO REGULATE PLANT GROWTH Bind-X GmbH (DE) 2022-06-02 WO claimed
WO-2014141181-A1 PROCESS FOR PREPARING PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LIMITED (GB) 2014-09-18 WO claimed
EP-1945717-A4 HIGH LINOLENIC LINSEED OIL COMPOSITIONS PETERSON LILLIAN (CA) 2009-05-13 EP claimed
EP-1945717-A1 HIGH LINOLENIC LINSEED OIL COMPOSITIONS Peterson, Lillian (CA) 2008-07-23 EP claimed
WO-2007051302-A1 HIGH LINOLENIC LINSEED OIL COMPOSITIONS PETERSON LILLIAN (CA) 2007-05-10 WO claimed
US-20060165640-A1 Cosmetic composition comprising at least one alkoxylated alcohol ester and at least one apolar oil L'OREAL S.A. (FR) 2006-07-27 US claimed
EP-0647184-B1 BIODEGRADABLE, LIQUID IMPERVIOUS MULTILAYER FILM COMPOSITIONS PROCTER & GAMBLE (US) 1998-03-11 EP claimed
EP-0404876-B1 LONG-CHAIN ALIPHATIC HYDROCARBYL AMINE ADDITIVES HAVING AN OXY-CARBONYL CONNECTING GROUP CHEVRON RES & TECH (US) 1995-02-15 EP claimed
US-3952049-A EXO-TRIMETHYLENENORBORNYL, OILING AGENTS KAO SOAP CO., LTD. (JA) 1976-04-20 US claimed
WO-2024073576-A1 4-((2-(3,5-DICHLOROPHENYL)-6-((PYRIMIDIN-5-YL)OXY)PYRIDIN-4-YL)METHYL)PIPERAZINE DERIVATIVES AS FURIN INHIBITORS AND USES THEREOF BP ASSET V, INC. (US) 2024-04-04 WO disclosed
US-20240108620-A1 Treatment Regimen GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-04-04 US disclosed
CN-111868071-B Novel dopamine precursors 耶路撒冷希伯来大学伊森姆研究发展有限公司 2024-03-26 CN disclosed
US-20240066133-A1 THERAPEUTIC AGENTS AND CONJUGATES THEREOF AJ SCIENCES (YIXING) CO., LTD (CN) 2024-02-29 US disclosed
EP-3993796-B1 COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM GLAXOSMITHKLINE IP DEV LTD (GB) 2024-02-21 EP disclosed
EP-0195846-A2 Photo-curable epoxy resin type composition and curing process KABUSHIKI KAISHA TOSHIBA (JP) 1986-10-01 EP disclosed
US-4528360-A Water-soluble film or sheet DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) 1985-07-09 US disclosed
EP-0123842-A1 Photo-curable epoxy resin type composition KABUSHIKI KAISHA TOSHIBA (JP) 1984-11-07 EP disclosed
EP-0114258-A1 Resin encapsulation type photo-semiconductor devices KABUSHIKI KAISHA TOSHIBA (JP) 1984-08-01 EP disclosed
EP-0015673-B1 3-AMINO-4-HOMOISOTWISTANE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1982-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108620-A1 Treatment Regimen GNAQ, GMPS, GNPDA1 EGLN1 2650/4885LMNA 3970/4885LDHA 2573/4885
US-20060165640-A1 Cosmetic composition comprising at least one alkoxylated alcohol ester and at least one apolar oil CUTA, KRT18, ALK EGLN1 1298/4885LMNA 584/4885LDHA 738/4885
US-20240066133-A1 THERAPEUTIC AGENTS AND CONJUGATES THEREOF TLR9, STING1, TLR3 EGLN1 3427/4885LMNA 1780/4885LDHA 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.